Anti-counterfeiting held back by self-interest & politics

Narrowly defined pharma self-interest and lack of coordinated political effort means, despite the best effort of some, the problem of counterfeiting may be worsening.

Anti-counterfeiting initiatives and technologies have gained prominence in recent years but political efforts have, to date, “generated far more heat than light”, according to a speaker at AAPS 2010.

Speaking at a mini-symposium Roger Bate, the Legatum Fellow in global prosperity at the American Enterprise Institute (AEI), said a lack of coordinated and dedicated effort is hindering anti-counterfeiting efforts.

On a basic level, the lack of a universally accepted definition of what a counterfeit is underpins many problems. Also, different views on the seriousness of counterfeiting leads to countries having very different punishments, ranging from fines to execution, making extradition impossible.

The practical implications of these differences were explained by another mini-symposium speaker, Aline Franco of Interpol. Franco said an important aspect of Interpol’s work is educating local police about why counterfeits are important and within their remit.

Different outlooks

On a global level different outlooks and interests, which are often influenced by domestic pharma industries, can be a source of friction. For instance, focus on intellectual property protection (IPP) by Western governments and companies can antagonise other countries, said Bate.

Detention of Indian generics in European ports, coupled to the drafting of legislation in Kenya and Uganda, has given countries reason to believe western anti-counterfeiting efforts are at least partly motivated by desire to strengthen IPP.

As a result these mid-income emerging nations have sustained a largely illogical campaign against nearly all efforts to combat fake drugs, including unfairly targeting WHO's (World Health Organization) efforts against counterfeit medicines”, said Bate.

The need for international cooperation is recognised by Interpol which coordinates the Operation Pangea anti-counterfeiting effort. Building on this, Franco said Interpol wants to have closer relationship with the US Pharmacopeia (USP), who also had a speaker at the mini-symposium.

International convention

Bate said a WHO-sponsored international convention to tackle counterfeiting is needed. By bringing all nations together in a transparent process focused on public health Bate believes a reasonable consensus document can be achieved.

In Bate’s opinion the convention should agree definitions for falsified medicines, push for similar offences and reasonably equivalent punishments in each jurisdiction and focus on improving public health.

Related News

PSM forms affiliate to tackle counterfeits in India

Top scientists and managers harder to recruit

MHRA: Full Force of UK Law Against Drug Counterfeiters

MHRA: Full Force of UK Law Against Drug Counterfeiters

FDA Cracks Down on Illegal Websites

FDA Cracks Down on Illegal Websites

ACTA finalised amid claims it creates trade barriers

Partnerships needed to beat public health counterfeit threat

USP building database of fake & substandard meds

Counterfeit antimalarials found in Ghanaian hospitals

Group forms for serialisation & ePedigree compliance

Anti-fake readiness a factor for emerging biotech buyers

USP and MENA government labs form Network to better drug quality

Week-long anti-counterfeiting effort confiscates 1m pills

FDA & WHO collaborate on surveillance of counterfeit drugs

Falsified APIs and gangsters in the pharma industry

Falsified APIs and gangsters in the pharma industry

Related Products

See more related products

Submit a comment

Your comment has been saved

Post a comment

Please note that any information that you supply is protected by our Privacy and Cookie Policy. Access to all documents and request for further information are available to all users at no costs, In order to provide you with this free service, William Reed Business Media SAS does share your information with companies that have content on this site. When you access a document or request further information from this site, your information maybe shared with the owners of that document or information.